| Literature DB >> 7579494 |
R V Iaffaioli1, A Tortoriello, G Facchini, M Santangelo, L Bucci, L Fei, N Di Martino, G Mantovani, F Caponigro.
Abstract
44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90% overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.Entities:
Mesh：
Substances：
Year: 1995 PMID： 7579494 DOI： 10.1007/BF00665975
Source DB: PubMed Journal: Breast Cancer Res Treat ISSN： 0167-6806 Impact factor: 4.872